Gene expression analysis of lung cancer.

OBJECTIVE: We aim to explore the expression difference between lung cancer cells and normal lung cells, and to investigate themechanismoflungcancerdevelopment.Be - sides, we predicted the potential target site of transcriptionalfactorsandmicroRNAsfordiffer - entially expressed genes (DEGs), which may helptoregulateexpressionofDEGs.Smallmol- eculeswerealsoidentifiedtocurelungcancer. MATERIALS AND METHODS: Gene expres - sion profiles we used were downloaded from Gene Expression Omnibus (GEO) using acces - sion number of GSE2378. Firstly, we identified differentialgenesbetweenlungcancercellsand normal lung cells by using R package limma. Then, we detected the processes and pathways that changed in lung cancer cells by Gene On - tology (GO) and KEGG pathway enrichment analysis.Potentialtargetsitesoftranscriptional factors and microRNAs were also detected based on gene annotation data in MSigDB. Fi- nally, small molecule drugs were screened via queryingConnectivityMapdatabase. RESULTS: We obtained 2961 differentially ex - pressed genes between lung cancer cells and normallungcells.Besideschangesincellcycle, metabolicprocessesandproteasomewerealso dramaticallydisordered.SomeDEGssharedtar - getsitesofthetranscriptionfactorsuchasE2F, ETS and CEBPB. Target sites of hsa-miR-196a and hsa-miR-200c were also significantly en - riched by DEGs. Iloprost simulated the state of normal cells, while MS-275 might be potential pathogenicsubstances. CONCLUSIONS: We investigate the lung can - cer from Gene Ontology, pathway, transcription factors and microRNAs based on gene expres - sion profiles. All these results may facilitate lungcancertreatmentwithanewbreakthrough.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  Carsten O. Daub,et al.  MiR-107 and MiR-185 Can Induce Cell Cycle Arrest in Human Non Small Cell Lung Cancer Cell Lines , 2009, PloS one.

[3]  J. Minna,et al.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? , 2010, Lung cancer.

[4]  Qi Zheng,et al.  GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis , 2008, Nucleic Acids Res..

[5]  E. Szabo.  Altered Histology Provides a Positive Clinical Signal in the Bronchial Epithelium , 2011, Cancer Prevention Research.

[6]  F. Shepherd,et al.  Therapy-related leukemia and myelodysplasia in small-cell lung cancer. Report of a case and results of morphologic, cytogenetic, and bone marrow culture studies in long-term survivors. , 1986, Archives of internal medicine.

[7]  Sean R. Davis,et al.  GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..

[8]  J. Otte,et al.  Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. , 2002, Genes & development.

[9]  Gareth Williams.  A searchable cross-platform gene expression database reveals connections between drug treatments and disease , 2012, BMC Genomics.

[10]  R. Enck,et al.  Lung cancer: diagnosis and management. , 2007, American family physician.

[11]  Chi-Ying F. Huang,et al.  Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. , 2012, American journal of respiratory and critical care medicine.

[12]  Jae Yong Cho,et al.  Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer , 2011, PloS one.

[13]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[14]  John D. Minna,et al.  miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1 , 2009, Molecular Cancer Research.

[15]  K. Bakır,et al.  Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study , 2012, Rheumatology International.

[16]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[17]  M. Matsuda,et al.  Delta-thalassemia caused by disruption of the site for an erythroid-specific transcription factor, GATA-1, in the delta-globin gene promoter. , 1992, Blood.

[18]  D. Slamon,et al.  RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. , 2010, Lung cancer.

[19]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[20]  G. V. Vande Woude,et al.  The decline in U.S. cancer mortality in people born since 1925. , 2009, Cancer research.

[21]  G. Blanck,et al.  Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. , 2009, Biological & pharmaceutical bulletin.

[22]  Julio Saez-Rodriguez,et al.  DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data , 2012, Bioinform..

[23]  B. Han,et al.  Hsa‐miR‐196a2 Functional SNP is Associated With Severe Toxicity After Platinum‐Based Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients in a Chinese Population , 2012, Journal of clinical laboratory analysis.

[24]  V. Pankratz,et al.  Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy , 2011, Clinical Cancer Research.

[25]  Sin Lam Tan,et al.  A database of annotated promoters of genes associated with common respiratory and related diseases. , 2012, American journal of respiratory cell and molecular biology.

[26]  P. Massion,et al.  Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin , 2012, Molecular Cancer Therapeutics.

[27]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[28]  H. Kato,et al.  Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[30]  Jonas Wittwer,et al.  Functional polymorphism in ALOX15 results in increased allele‐specific transcription in macrophages through binding of the transcription factor SPI1 , 2006, Human mutation.

[31]  A. Metspalu,et al.  Metagenes Associated with Survival in Non-Small Cell Lung Cancer , 2011, Cancer informatics.

[32]  Chi-Ying F. Huang,et al.  Gene expression‐based chemical genomics identifies heat‐shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma , 2013, Cancer.

[33]  Libing Song,et al.  Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival , 2009, Cancer.

[34]  C. S. Ricard,et al.  Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray , 2002, Glia.

[35]  M. Tennis,et al.  Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. , 2010, Neoplasia.

[36]  T Takahashi,et al.  The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells , 2013, Oncogene.

[37]  Shu Zheng,et al.  MicroRNA‐183 regulates Ezrin expression in lung cancer cells , 2008, FEBS letters.

[38]  I. Kohane,et al.  DNA hypermethylation in lung cancer is targeted at differentiation-associated genes , 2012, Oncogene.

[39]  J. Brouwer-Visser,et al.  Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1–dependent , 2010, Proceedings of the National Academy of Sciences.

[40]  P. Massion,et al.  DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway , 2010, Oncogene.

[41]  L. Rasmussen,et al.  The role of mismatch repair in small-cell lung cancer cells. , 2003, European journal of cancer.

[42]  M. You,et al.  Lung cancer chemoprevention: difficulties, promise and potential agents? , 2013, Expert opinion on investigational drugs.

[43]  F. Khuri.  The Dawn of a Revolution in Personalized Lung Cancer Prevention , 2011, Cancer Prevention Research.

[44]  Yusuke Nakamura,et al.  Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. , 2006, Cancer research.

[45]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[46]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[47]  O. Eickelberg,et al.  What shall we do with the damaged proteins in lung disease? Ask the proteasome! , 2012, European Respiratory Journal.

[48]  T. Dønnem,et al.  MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer , 2012, PloS one.

[49]  T. Mukhopadhyay,et al.  Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells , 2012, The Journal of Biological Chemistry.

[50]  M. Bernstein,et al.  Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells , 2008, Cancer Cell International.

[51]  H. Bai,et al.  Transcriptional regulatory networks in human lung adenocarcinoma. , 2012, Molecular medicine reports.